BIO Thanks Congressmen and Senators for Clearing a Path for Military Biofuel Producers

BIO Thanks Congressmen and Senators for Clearing a Path for Military Biofuel Producers

<0> Biotechnology Industry Organization, 202-962-9237Web: Blog: Twitter: </0>

The Biotechnology Industry Organization (BIO) today thanked members of the House and Senate Armed Services Committees for finalizing the National Defense Authorization Act of 2013 and clearing the path for the Department of Defense (DoD) to participate in public-private partnerships to produce advanced biofuels. BIO President and CEO Jim Greenwood released the following statement:

“Military leaders have recognized that building a domestic advanced biofuels industry to produce cost-competitive fuels is a national security priority. They have responded to this need in the same way the United States has responded to similar challenges in the past – by proposing public-private partnerships to produce the needed materials.

“Already, several private companies have made significant investments to develop advanced biofuels for military applications. The National Defense Authorization Act – with final passage by Congress and the President’s signature – will clear the path for the Department of Defense to participate with other federal agencies in partnership with these private companies to finish the job.

“Private investment is critical to ensuring that advanced biofuels become cost-competitive, reach commercial scale and can be widely used by the Department, the commercial aviation sector and others. Policy stability is crucial to maintaining investment in fuels that meet the U.S. military’s current mission needs and provide benefits for future needs. We thank the members of the conference committee for maintaining the current policy on the environmental profile of fuels.”

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces , an online portal and monthly newsletter chronicling “innovations transforming our world.” .

January 29 – 30, 2013Tokyo, Japan

February 11 – 12, 2013New York City, NY

April 22 – 25, 2013Chicago, IL

June 16 – 19, 2013Montreal, Quebec, Canada

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.